Company intelligence / Profile preview

Anelixis Therapeutics

Cambridge, Massachusetts, USAin.marketscreener.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Developed anti-CD40L antibody AT-1501 showing safety in Phase 1 and progressing through multiple Phase 2 trials. Demonstrated graft protection in non-human primate transplant models and early clinical activity in ALS and type 1 diabetes.

Therapeutic areas: HematologyImmunologyNeurologyEndocrinology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

tegoprubart

Phase 2

Indications: Organ transplant rejection, Type 1 diabetes, ALS

Partnerships

ALS Therapy Development Institute (2015 licensing agreement)Health Canada (clinical trial clearance)

Beyond the preview

Go deeper on Anelixis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anelixis Therapeutics.

Explore the full profile